Skip to search formSkip to main contentSkip to account menu

rolapitant 90 MG Oral Tablet [Varubi]

Known as: ROLAPITANT HYDROCHLORIDE 90 mg ORAL TABLET [Varubi], VARUBI 90 MG Oral Tablet 
National Institutes of Health

Related topics

Related topics

11 relations
Croscarmellose SodiumLactose MonohydrateMagnesium stearateOral Tablet

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Rolapitant: A Review in Chemotherapy-Induced Nausea and Vomiting
Oral rolapitant (Varubi™; Varuby®), a long-acting neurokinin-1 (NK1) receptor antagonist (RA), is indicated in the USA and EU as… 
Review
2016
Review
2016
Systematic Review Of The Efficacy And Safety Of Neurokinin-1 Receptor Antagonists For Chemotherapy-Induced Nausea And Vomiting: Identification Of The Relevant Clinical Trials
Review
2015
Review
2015
Rolapitant: First Global Approval
Rolapitant (Varubi™) is an orally active neurokinin-1 receptor antagonist developed by TESARO and approved in the USA for use in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)